...
首页> 外文期刊>The National medical journal of India >C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia
【24h】

C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia

机译:MDR1基因中的C1236T多态性与印度慢性粒细胞白血病患者对甲磺酸伊马替尼的治疗反应相关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Patients with chronic myeloid leukaemia show an excellent response to treatment with imatinib. However, in some patients, the disease is resistant to imatinib. This resistance may be related to the presence of genetic variations on the drug's pharmacokinetics and metabolism. We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib. Imatinib resistance was more frequent in patients with TT genotype at locus 1236 than in those with CT/CC genotypes (p = 0.003). For the other two loci (G2677T and C3435T), resistance was seen to be higher for TT genotype when compared to GG/GT and CT/CC but it was not statistically significant (p = 0.13 and p = 0.099). In conclusion, determination of C1236T MDR1 genotype may help to predict response to imatinib therapy in patients with chronic myeloid leukaemia.
机译:患有慢性粒细胞白血病的患者对伊马替尼治疗表现出出色的反应。但是,在某些患者中,该病对伊马替尼有抗药性。这种抗药性可能与药物药代动力学和代谢中遗传变异的存在有关。因此,我们在86名伊马替尼治疗的慢性粒细胞白血病患者中研究了人类多药耐药基因(MDR1)中的三种多态性(C1236T,G2677T和C3435T)。 1236位基因型TT基因型患者的伊马替尼耐药率高于CT / CC基因型患者(p = 0.003)。对于其他两个基因座(G2677T和C3435T),与GG / GT和CT / CC相比,TT基因型的耐药性更高,但无统计学意义(p = 0.13和p = 0.099)。总之,确定C1236T MDR1基因型可能有助于预测慢性粒细胞白血病患者对伊马替尼治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号